(Taken directly from the application) The overarching mission of the MB/MG Core is to discover the molecular bases underlying obesity and its comorbidities. To achieve this mission, the Core performs studies in humans and rodents to identify mutations in candidate genes as well as rodent studies to define the functions of candidate genes by genetic manipulations using transgenic methodologies. Through collaborative efforts with other Cores of the NYORC, the effects of defined genetic alterations in humans and rodents are thoroughly characterized for their effects on ingestive behavior, energy balance, body composition, and endocrine function. The role of candidate molecules in relevant tissues, such as neurons, adipocytes and pancreatic islets, which are related to energy homeostasis can be sharply delineated by thorough and definitive experimentation on both human subjects and rodent models. Due to the establishment of dose ties among the various Cores of the NYORC, opportunities to explore new genetic models of obesity are greeted with enthusiasm by the collaborators of the MB/MG Core. The addition of the Columbia University Microarray Facility (under the direction of Dr. Anthony Ferrante) to the Columbia Genome Center and the Division of Molecular Genetics (Drs. Leibel and Chua are members of the Division) allows the massively parallel analysis of gene expression in models of obesity. The broad expertise of the MB/MG staff allows the MB/MG Core to make available to biomedical investigators a wide range of methodologies and reagents relevant to understanding the molecular physiology of obesity and energy metabolism in animals and humans. This core applies molecular genetic and molecular biological techniques to the mapping, cloning and functional characterization of genes related to obesity and its comorbidities (diabetes and atherosclerosis). The services of this core are available to investigators new to obesity research, as well as to investigators working on obesity related projects that can be enriched and extended by the use of the facilities of this core.

Project Start
2001-12-01
Project End
2002-11-30
Budget Start
Budget End
Support Year
22
Fiscal Year
2002
Total Cost
Indirect Cost
Name
St. Luke's-Roosevelt Institute for Health Sciences
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10019
Carli, Jayne F Martin; LeDuc, Charles A; Zhang, Yiying et al. (2018) The role of Rpgrip1l, a component of the primary cilium, in adipocyte development and function. FASEB J 32:3946-3956
Gallagher, Dympna; Rosenn, Barak; Toro-Ramos, Tatiana et al. (2018) Greater Neonatal Fat-Free Mass and Similar Fat Mass Following a Randomized Trial to Control Excess Gestational Weight Gain. Obesity (Silver Spring) 26:578-587
Rosenbaum, Michael; Goldsmith, Rochelle L; Haddad, Fadia et al. (2018) Triiodothyronine and leptin repletion in humans similarly reverse weight-loss induced changes in skeletal muscle. Am J Physiol Endocrinol Metab :
Gallagher, Dympna; Rizkalla, Bridgette (2018) The 11th International Symposium on In Vivo Body Composition Studies. Eur J Clin Nutr :
Iqbal, Niloy Jafar; Lu, Zhonglei; Liu, Shun Mei et al. (2018) Cyclin-dependent kinase 4 is a preclinical target for diet-induced obesity. JCI Insight 3:
Martin Carli, Jayne F; LeDuc, Charles A; Zhang, Yiying et al. (2018) FTO mediates cell-autonomous effects on adipogenesis and adipocyte lipid content by regulating gene expression via 6mA DNA modifications. J Lipid Res 59:1446-1460
Blumenfeld, Nicole R; Kang, Hwan June; Fenzl, Anna et al. (2018) A direct tissue-grafting approach to increasing endogenous brown fat. Sci Rep 8:7957
Ravussin, Yann; Edwin, Ethan; Gallop, Molly et al. (2018) Evidence for a Non-leptin System that Defends against Weight Gain in Overfeeding. Cell Metab 28:289-299.e5
Shechter, Ari; Kim, Elijah Wookhyun; St-Onge, Marie-Pierre et al. (2018) Blocking nocturnal blue light for insomnia: A randomized controlled trial. J Psychiatr Res 96:196-202
Sui, Lina; Danzl, Nichole; Campbell, Sean R et al. (2018) ?-Cell Replacement in Mice Using Human Type 1 Diabetes Nuclear Transfer Embryonic Stem Cells. Diabetes 67:26-35

Showing the most recent 10 out of 809 publications